In an exploratory KEYNOTE-B15 analysis, ctDNA clearance was higher with enfortumab vedotin plus pembrolizumab than with cisplatin and gemcitabine.
|Articles|April 3, 2014
Exploring Alternate Payment Models in Oncology
Author(s)Jessica Turgon, MBA
At the ACCC annual meeting, Jessica Turgon, MBA, from ECG Management Consultants discusses how and why providers and payers are beginning to work together to explore alternate payment models in oncology.
Advertisement
At the Association for Community Cancer Centers 40th Annual National Meeting, Jessica Turgon, MBA, from ECG Management Consultants discusses how and why providers and payers are beginning to work together to explore alternate payment models in oncology.
Advertisement
Related to this article
Subgroup analyses of the phase 3 RASolute 302 trial showed overall survival favored daraxonrasib over chemotherapy in metastatic pancreatic cancer.
Adding pembrolizumab to carboplatin and etoposide improved response rates and OS vs chemotherapy alone in metastatic NEPC in KEYNOTE-365 cohort I.
Posters covered a companion diagnostic for niraparib plus AAP, response biomarkers for radioligand therapy, and genomic profile differences in metastatic CRPC.
Six-year NATALEE data show ribociclib plus an NSAI reduced the risk of death by 19% vs NSAI alone in HR+/HER2- early breast cancer.
Final NSABP B-42 data show 5 additional years of letrozole improved DFS, BCFI, and distant recurrence vs placebo at 15 years, with no OS difference.
Perioperative pembrolizumab plus neoadjuvant cisplatin and gemcitabine did not significantly improve EFS vs placebo in cisplatin-eligible MIBC in KEYNOTE-866.
Hope S. Rugo, MD, FASCO, and Irene M. Kang, MD, discussed ASCENT-03, -04, and TROPION-Breast02 data, sequencing, and toxicity in metastatic TNBC.
Advertisement
Advertisement
Trending on CancerNetwork
1
Intismeran Plus Pembrolizumab Reduces Recurrence Risk in Resected Melanoma
2
What Pope Leo XIV’s Lung Cancer Diagnosis Could Mean for Stigma & Nihilism
3
Zipalertinib May Introduce Another Option to EGFR Exon 20+ NSCLC
4
Rethinking Patient Selection Strategy for Phase 1 Breast Cancer Trials
5